Page last updated: 2024-11-12

1-deoxynojirimycin hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID13018787
CHEMBL ID460785
SCHEMBL ID1320203
MeSH IDM0329224

Synonyms (41)

Synonym
1-deoxynojirimycin hydrochloride
sc-48305 ,
duvoglustat hydrochloride
at-2220
hgt-3510
deoxynojirimycin hydrochloride
moranolin hydrochloride
CHEMBL460785
at2220
duvoglustat hcl
moranoline hydrochloride
1 deoxynojirimycin hydrochloride
D09606
duvoglustat hydrochloride (usan)
73285-50-4
SCHEMBL1320203
1,5-dideoxy-1,5-imino-d-sorbitol hydrochloride
(2r,3r,4r,5s)-2-(hydroxymethyl)piperidine-3,4,5-triol hydrochloride
moranoline hcl
3,4,5-piperidinetriol, 2-(hydroxymethyl)-, hydrochloride (1:1), (2r,3r,4r,5s)-
at 2220
duvoglustat hydrochloride [usan]
0rn23c42qr ,
unii-0rn23c42qr
355138-93-1
1-deoxy-l-altronojirimycin hydrochloride
3,4,5-piperidinetriol, 2-(hydroxymethyl)-, hydrochloride, (2r,3r,4r,5s)-
3,4,5-piperidinetriol, 2-(hydroxymethyl)-, hydrochloride, (2r-(2.alpha.,3.beta.,4.alpha.,5.beta.))-
(+)-1-deoxynojirimycin hydrochloride
AKOS030253224
AS-60890
F19165
deoxynojirimycin hcl
HY-14860A
DTXSID401017351
dnjat2220
CS-0101849
Q27237146
73285-50-4 (hcl)
(2r,3r,4r,5s)-2-(hydroxymethyl)piperidine-3,4,5-triol;hydrochloride
EN300-19636275
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cannabinoid receptor 1Rattus norvegicus (Norway rat)IC50 (µMol)10.00000.00020.660910.0000AID493446
Killer cell lectin-like receptor subfamily B member 1ARattus norvegicus (Norway rat)IC50 (µMol)10.00001.99534.835710.0000AID493446
Early activation antigen CD69Homo sapiens (human)IC50 (µMol)630.95703.10003.10003.1000AID493447
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (1)

Processvia Protein(s)Taxonomy
cellular response to xenobiotic stimulusEarly activation antigen CD69Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
transmembrane signaling receptor activityEarly activation antigen CD69Homo sapiens (human)
protein bindingEarly activation antigen CD69Homo sapiens (human)
carbohydrate bindingEarly activation antigen CD69Homo sapiens (human)
identical protein bindingEarly activation antigen CD69Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
plasma membraneEarly activation antigen CD69Homo sapiens (human)
protein-containing complexEarly activation antigen CD69Homo sapiens (human)
external side of plasma membraneEarly activation antigen CD69Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID1272276Inhibition of yeast type-3 alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate after 30 mins2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Synthesis, in vitro and computational studies of 1,4-disubstituted 1,2,3-triazoles as potential α-glucosidase inhibitors.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID391607Inhibition of Bacillus stearothermophilus alpha-glucosidase2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Chlorogenic acid derivatives with alkyl chains of different lengths and orientations: potent alpha-glucosidase inhibitors.
AID1463975Inhibition of wild type recombinant EGFR (unknown origin) at 50 nM by ELISA relative to control2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Quinazoline-1-deoxynojirimycin hybrids as high active dual inhibitors of EGFR and α-glucosidase.
AID493446Activation of rat NKR-P1A2010Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15
Deoxynojirimycin and its hexosaminyl derivatives bind to natural killer cell receptors rNKR-P1A and hCD69.
AID1142530Inhibition of yeast alpha-glucosidase type 3 using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated with substrate for 5 mins prior to enzyme challenge for 30 mins by absorbance analysis2014European journal of medicinal chemistry, Jun-10, Volume: 80Dual inhibition of the α-glucosidase and butyrylcholinesterase studied by molecular field topology analysis.
AID493447Activation of human CD692010Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15
Deoxynojirimycin and its hexosaminyl derivatives bind to natural killer cell receptors rNKR-P1A and hCD69.
AID1463973Inhibition of wild type recombinant EGFR (unknown origin) by ELISA2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Quinazoline-1-deoxynojirimycin hybrids as high active dual inhibitors of EGFR and α-glucosidase.
AID1463974Inhibition of recombinant alpha-glucosidase (unknown origin) using PNP-G as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by spectrophotometric analysis2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Quinazoline-1-deoxynojirimycin hybrids as high active dual inhibitors of EGFR and α-glucosidase.
AID391608Inhibition of Saccharomyces cerevisiae alpha-glucosidase2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Chlorogenic acid derivatives with alkyl chains of different lengths and orientations: potent alpha-glucosidase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.74 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]